Net sales grew 6.5% year-on-year in FY2025 1H, led by new drugs and generics, while operating profit declined due to higher R&D costs. Interim results exceeded forecasts for sales and net profit, and the company maintained its full-year guidance and dividend policy.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.